Home >> A 350619 hydrochloride
Related Products
A 350619 hydrochloride
Activator of soluble guanylyl cyclase (sGC)

Catalog No.B5336
Size Price Stock Qty
10mM (in 1mL DMSO)
$130.00
In stock
10mg
$186.00
In stock
50mg
$787.00
In stock

Tel: +1-832-696-8203

Email: [email protected]

Worldwide Distributors

      

Sample solution is provided at 25 µL, 10mM.

Quality Control

Quality Control & MSDS

View current batch:

Chemical structure

A 350619 hydrochloride

A 350619 hydrochloride Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

A 350619 hydrochloride Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Chemical Properties

Cas No. 1217201-17-6 SDF Download SDF
Chemical Name (1Z,2E)-3-(2-((4-chlorophenyl)thio)phenyl)-N-(4-(dimethylamino)butyl)acrylimidic acid hydrochloride
Canonical SMILES CN(CCCC/N=C(O)/C([H])=C([H])/C1=CC=CC=C1SC2=CC=C(Cl)C=C2)C.Cl
Formula C21H25ClN2OS.HCl M.Wt 425.41
Solubility >21.3mg/mL in DMSO Storage Store at -20°C
Physical Appearance White solid Shipping Condition Evaluation sample solution : ship with blue ice.All other available size: ship with RT , or blue ice upon request
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.

Background

Km: 50 μM

Nitric oxide (NO) is a key mediator in many physiological processes and one of the key receptors through which NO exerts its effects is soluble guanylyl cyclase (GC). Guanylyl cyclase converts GTP to cyclic GMP that results in physiological processes such as smooth muscle relaxation, neurotransmission, platelet aggregation inhibition and immune response. A 350619 is a novel soluble guanylyl cyclase activator.

In vitro: A 350619 increased Vmax from 0.1 to 14.5 μmol/min/mg, and lowered Km from 300 to 50 μM. When A 350619 and YC-1 (another GC activator) were combined, a 156 fold increase in Vmax and a 5 fold decrease in Km were observed, indicating the modulation of the enzyme brought about by YC-1 and A 350619 are not additive, indicating a common binding site. Activation of soluble guanylyl cyclase by A 350619 was partially inhibited by ODQ, a specific inhibitor of soluble guanylyl cyclase by oxidation of the enzyme heme [1].

In vivo: Consistent with its biochemical activity, in a conscious rat model, A 350619 (1 μmol/kg) alone induced penile erection. Activation of soluble guanylyl cyclase in cavernosum tissue as an alternate method of enhancing the effect of NO may provide a novel treatment of sexual dysfunction [2].

Clinical trial: Up to now, A 350619 is still in the preclinical development stage.

Reference:
[1] Miller LN, Nakane M, Hsieh GC, Chang R, Kolasa T, Moreland RB, Brioni JD.  A 350619: a novel activator of soluble guanylyl cyclase. Life Sci. 2003 Jan 17;72(9):1015-25.